Welcome to our dedicated page for Tevogen Bio SEC filings (Ticker: TVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tevogen Bio Holdings Inc. (TVGN) SEC filings page on Stock Titan aggregates the company’s official disclosures from the U.S. Securities and Exchange Commission, offering a structured view into this clinical-stage biotechnology issuer’s regulatory record. As a Nasdaq-listed company, Tevogen files periodic reports and current reports that detail its financial performance, operating strategy, and material events.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, management’s discussion and analysis, and commentary on Tevogen’s capital-efficient, cost-disciplined business model. For a company focused on precision T cell therapies and AI-enabled drug discovery, these filings provide context on research and development spending, general and administrative expenses, and non-GAAP measures such as adjusted loss from operations that Tevogen uses to describe operational performance.
Current reports on Form 8-K capture significant events, including listing and compliance matters. For example, Tevogen disclosed via Form 8-K that it received a Nasdaq notice regarding non-compliance with the $1.00 per share minimum bid price requirement, outlining the applicable compliance period and potential paths to regain compliance. Such filings help investors understand listing status and associated timelines.
The filings page also offers access to information related to equity structure, warrants, and other securities, as well as any proxy materials and, where applicable, insider transaction reports on Form 4. Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping users quickly identify items such as changes in operating loss, capital structure, or risk disclosures. Real-time updates from EDGAR ensure that new TVGN filings, from 10-Qs to 8-Ks, appear promptly with accessible explanations for investors analyzing Tevogen’s financial and regulatory trajectory.
Tevogen Bio Holdings Inc. reported that it received a notice from Nasdaq on September 23, 2025 stating that its common stock no longer meets the Nasdaq Global Market’s $1.00 per share minimum bid price requirement under Listing Rule 5450(a)(1). This determination was based on the stock’s closing bid price over the previous 30 consecutive business days, but the notice does not immediately affect the stock’s listing or trading status.
The company has 180 calendar days, until March 23, 2026, to regain compliance. It will be considered back in compliance if the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days and generally not more than 20 consecutive business days. If compliance is not restored by that date, Tevogen may seek an additional 180-day period by transferring to the Nasdaq Capital Market and meeting that market’s other initial listing standards.
Tevogen states that it will monitor the closing bid price and the market integrity of its common stock and may evaluate options to regain compliance, but it cautions that there is no assurance it will take any specific action or succeed in maintaining compliance with Nasdaq’s listing rules.